Table 1 Clinical outcome from different doses and influence of PDT treatment
From: Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies
References | Study design | Participants | Dosage (Full dose or half, 1/3 dose) | Duration (Months, M) | Results |
|---|---|---|---|---|---|
Chan et al. (2003) [108] | Prospective study | 6 eyes with persistent or cCSCR | Full-dose PDT | 12.7 | Succeeding to stop fluorescein leakage without recurrence of CSCR |
Chan et al. (2008) [106] | Prospective study | 48 eyes with cCSCR | Half-dose PDT | 12 | Resolution of SRF and improvement of BCVA |
Chan et al. (2008) [102] | Prospective study, RCT | 63 eyes with aCSCR | Half-dose PDT vs. placebo | 12 | Absence of exudative macular detachment and improvement of VA |
Zhao et al. (2009) [113] | Prospective study | 15 eyes with aCSCR | 70%, 60%, 50%, 40%, 30%, 20%, and 10% of full dose PDT | 12 | One-third-dose is safe and effective in the treatment of aCSCR |
Bae et al. (2011) [117] | Prospective, a single pilot study | 16 eyes with cCSCR | Low-fluence PDT vs. intravitreal injections of ranibizumab | 3 | Ranibizumab injections was not promising compared with low-fluence PDT in terms of anatomic outcomes |
Uetani et al. (2012) [105] | Prospective study | 16 eyes with cCSCR | Half-dose PDT vs. one-third-dose PDT | 3 | Half-dose PDT is more effective in resolution of SRF |
Kim et al. (2014) [111] | Retrospective study | 21 eyes with aCSCR | Half-dose PDT vs. observation | 12 | Rapid resolution of SRF in aCSCR by half-dose PDT |
Kim et al. (2015) [118] | Retrospective study | 57 eyes with cCSCR | Half-dose PDT vs. half-fluence PDT | 24–62 | CRT changes reflect PDT efficacy and predict long-term recurrence and early treatment outcomes |
Fujita et al. (2015) [107] | Retrospective study | 204 eyes with cCSCR | Half-dose PDT | 12 | Effective in treating SRD and BCVA improved significantly |
Cheng CK et al. (2017) [110] | Prospective study, RCT | 40 eyes with cCSCR | Half-dose PDT vs. half-fluence PDT | 6 | Both half-dose and half-fluence PDT were similarly effective in improving VA and SRF for cCSCR |
van Dijk et al. (2018) [116] | RCT | 179 patients with cCSCR | Half-dose PDT vs. high-density subthreshold micropulse laser (HSML) | 8 | Half-dose PDT is superior to HSML for treating cCSCR |
Hua et al. (2018) [[112] | Retrospective study | 68 eyes with cCSCR | One-third dose PDT | 6 | Improvement of BCVA, reduces choroidal vasodilatation and leakage, accelerates absorption of SRF, and prompt recovery of photoreceptors |
van Rijssen et al. (2021) [115] | Retrospective study | 34 eyes with cCSCR | Half-dose PDT | 12 | SRF and BCVA were improved |
Pichai et al. (2021) [[114] | Retrospective study | 46 eyes with recurrent or cCSCR | Half-dose PDT vs. one-third-dose PDT | 12 | One-third-dose PDT was effective in improving BCVA and CRT but had higher recurrence rate of SRF |